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CASE PRESENTATION
A 51-year-old woman was admitted to the hospi-
tal for coronary angiography due to recurrent angina.
In 1990 she had developed nephrotic syndrome. Kid-
ney biopsy revealed focal segmental glomerulosclerosis.
Steroid therapy was initiated, but the patient responded
only partially. Cyclosporine A was added. She developed
hyperuricemia and was given allopurinol. Days later,
acute renal failure ensued. Renal biopsy demonstrated
acute allergic interstitial nephritis due to allopurinol. Al-
lopurinol was withdrawn, and her renal function returned
to normal after some weeks.
In the following years, focal segmental glomeruloscle-
rosis progressed to end-stage renal disease. Hyper-
uricemia persisted, and she developed hypertension and
concentric left-ventricular hypertrophy. Because of non-
compliance with her prescribed medications, the patient
had a long history of hyperphosphatemia and secondary
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hyperparathyroidism (intact parathyroid hormone levels
up to 2000 pg/mL). Parathyroidectomy was repeatedly
recommended and finally performed in 2000. Hemodial-
ysis was started in 2001; the creatinine clearance was
3.5 mL/min when she was severely uremic (recommenda-
tions for an earlier start of hemodialysis had been rejected
by the patient). She also had rejected a potential kidney
donation by her parents and her brother. Vascular abnor-
malities in the patient included increased intima-media
thickness and hardening of the common carotid artery,
calcification of coronary arteries, and severe peripheral
artery disease.
DISCUSSION
DR. WALTER H. HO¨RL (Division of Nephrology, De-
partment of Medicine III, Medical University of Vienna,
Vienna, Austria): Excess mortality rates have been de-
scribed in end-stage renal disease (ESRD) patients, par-
ticularly in young dialysis patients as compared to the
general population [1]. Atherosclerosis, more common
and more severe in uremic patients than in the general
population, occurs very early in renal disease. Acceler-
ated atherosclerosis in uremic patients was initially de-
scribed by Lindner et al three decades ago [2]. Rapid ap-
pearance of advanced coronary lesions was seen in young
adults with childhood-onset chronic renal failure [3]. Vas-
culopathy has been reported in one-third of the patients
with chronic kidney disease, even in early stages of the dis-
ease [4]. A high prevalence of atherosclerotic lesions and
increased intima-media thickness (IMT) is a contributing
factor to morbidity and mortality in ESRD patients [5].
Moreover, atherosclerotic plaques grow faster in a ure-
mic environment [6]. The extraordinary extent of vascular
disease in uremic patients cannot be entirely explained by
the prevalence of established risk factors for atheroscle-
rosis such as advanced age, male gender, hypertension,
diabetes, smoking, or dyslipidemia [7]. Therefore, addi-
tional risk factors for arteriosclerosis, atherosclerosis, and
vascular calcification have to be considered in ESRD pa-
tients. In this Forum, I plan to focus on the role of oxida-
tive and carbonyl stress, increased blood levels of homo-
cysteine, nitric oxide inhibition, and phosphate retention
in this near-epidemic of vasculopathy in uremia.
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Fig. 1. Relationship between levels of advanced oxidation protein
products (AOPPs) and advanced glycation end products (AGEs)-
pentosidine in 56 patients with chronic renal failure (17).
Oxidative stress and carbonyl stress
Increased oxidative stress has been implicated in the
development of atherogenesis and cardiovascular com-
plications for ESRD patients [8]. The degree of oxidant
stress is related to the severity of kidney disease. Low-
grade inflammation also plays an important role in the
pathogenesis of atherosclerosis, and long-standing oxida-
tive stress increases the inflammation state [9].
Generation of oxidant species is caused enzymatically
by, for example, xanthine oxidase, NAD(P)H oxidase,
endothelial nitric oxide synthase (NOS), lipoxygenase
and/or myeloperoxidase, as well as by transition met-
als, such as iron. Antioxidant defenses include super-
oxide dismutase, catalase, glutathione peroxidase, trace
metal scavengers and nonenzymatic substances such as
melatonin, tocopherol, ascorbic acid, carotenoids, and
flavonoids. An imbalance between reactive oxygen radi-
cal production and antioxidant defense occurs in uremia
[6].
Plasma concentration of malondialdehyde (MDA) sig-
nificantly increases with the impairment of kidney func-
tion, while the glutathione peroxidase activity decreases
progressively. Reactive oxygen species (ROS) produc-
tion, lipid peroxidation, and the imbalance of plasma
antioxidant enzyme activities are more accentuated in
maintenance dialysis patients, and these alterations re-
sult in accumulation of free radical species and oxidation
of susceptible molecules [10]. Cigarette smoking has an
additive, negative impact on plasma-circulating products
of lipid peroxidation in hemodialysis patients. Smoking
increases free-radical–mediated oxidative damage of crit-
ical biologic substances and aggravates oxidative stress in
the body of hemodialysis patients. The low plasma ascor-
bate levels, particularly in hemodialysis patients who
smoke [11], make these patients more susceptible to ox-
idative tissue damage than nonsmoking hemodialysis pa-
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Fig. 2. Correlation between wall-to-lumen ratio of common carotid
artery (CCA) and advanced oxidation protein products (AOPPs) in
hemodialysis patients (31).
tients or healthy subjects [11]. Renal anemia aggravates
oxidative stress. Oxidative stress is not only associated
with atherosclerosis but also with hypertension [12].
Uremic atherosclerosis is associated with the genera-
tion of advanced glycation end products (AGEs) [13].
Irreversible advanced glycation of proteins is part of the
aging process, which is markedly amplified in diabetes
and uremia. Potential uremic toxins, AGEs might play
an important role in the pathogenesis of accelerated vas-
cular complications, particularly in diabetes and ESRD
patients. AGEs might activate monocytes/macrophages
and endothelial cells and result in release of cytokines
and growth factors [14]. AGEs also might contribute to
oxidative stress, inflammation, an increase in extracellu-
lar matrix, and abnormal cell proliferation [13, 14]. The
demonstration that injection of the extracellular domain
of the receptor of AGE reduced atherosclerotic plaques
in diabetic apo-lipoprotein E knockout mice supports
their role in atherosclerosis [15].
Nonspecific AGEs are two- to threefold elevated in
uremic patients, while plasma levels of pentosidine rise
approximately tenfold without any difference between
diabetic and nondiabetic uremic patients. Total and
protein-bound carboxymethyllysine (CML) levels are
three- to fivefold higher than in healthy subjects [16].
AGE levels correlate with markers of oxidative stress
such as advanced oxidation protein products (AOPPs)
and lipid peroxidation markers; this finding suggests that
accumulation of dicarbonyls and subsequent AGE for-
mation in uremia occur mainly because of increased ox-
idative stress [13, 17]. MDA and other lipid-peroxidation-
product–modified proteins are called advanced
lipoxidation end products (ALEs) [13].
Accumulation in uremic plasma of reactive car-
bonyl compounds (RCOs), constantly produced by the
metabolism of carbohydrates, lipids, and amino acids, and
best described as “carbonyl stress,” results in AGE and
Nephrology Forum: Atherosclerosis and uremic toxins 1721
1.0
0.9
0.8
0.7
0 6.7 13.3 20.0 26.7 33.3 40.0
Cu
m
u
la
tiv
e
 s
u
rv
iva
l
Time, months
I tertile
II tertile
III tertile
Fig. 3. Cox proportional hazard survival curves for fatal and nonfatal
atherothrombotic events according to plasma homocysteine (I tertile,
<22.9 lmol/L; III tertile,>37.8 lmol/L) in hemodialysis patients (41).
ALE formation. AGEs/ALEs such as pentosidine, CML,
malondialdehydelysine, imidazolone, and glyoxal-lysine
dimer, as well as RCOs such as 3-deoxyglucosone, MDA,
and arabinose, accumulate in uremia. Causes of uremic
carbonyl stress are increased RCO production by oxida-
tive stress and impaired RCO detoxification by a decrease
of glomerular filtration rate [18]. AGEs and ALEs were
detected in the fatty streaks and thickened neointima of
arteries [19]. In ESRD patients, a close association ex-
ists between lipid peroxidation and glycoxidation, indi-
cating also a close relationship between nonenzymatic
glycosylation and oxidation [20]. Glycoxidation reactions
result in the formation of irreversible protein modifi-
cations and cross-links, such as CML and pentosidine
[13].
3-Deoxyglucosone could play a principal role in the
development of uremic complications such as atheroscle-
rosis. 3-Deoxyglucosone accumulates in the serum and
red blood cells of uremic patients. It rapidly reacts with
protein amino groups to form AGEs. The most specific
AGE for 3-deoxyglucosone is imidazolone. The accumu-
lation of 3-deoxyglucosone in erythrocytes of dialysis pa-
tients might increase oxidative stress. 3-Deoxyglucosone
inactivates intracellular antioxidant enzymes, such as glu-
tathione reductase and glutathione peroxidase, a key an-
tioxidant enzyme for detoxifying peroxide [21].
The formation of reactive aldehydes, such as gly-
oxal, methylglyoxal, acrolein, glycoaldehyde, and parahy-
droxyl phenacetaldehyde [13] in uremia results in
carbonyl stress. Reactive carbonyl compounds can be de-
tected in uremia in concentrations far in excess of those
in healthy subjects [13, 22]. These compounds play an im-
portant role in AGE formation. Reactive aldehydes and
AGEs play a prominent role in the pathogenesis of vas-
cular disease, including atherosclerosis [23]. AGEs might
promote atherosclerosis through interactions with spe-
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Fig. 4. Plasma asymmetric dimethylarginine (ADMA) concentrations
in healthy control subjects, patients with peripheral arterial occlusive
disease (PAOD), and patients with end-stage renal disease (ESRD)
without or with concomitant atherosclerosis (66).
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Fig. 5. Phosphate regulation of ectopic calcification in human aortic
smooth muscle cells cultured in media containing different phosphate
(PI) concentrations (79).
cific receptors and cause increased expression of adhesion
molecules, increased attraction of circulating monocytes
to the vessel wall, increased production of interleukin-6
by monocytes, and excess formation of C-reactive protein
in the liver [24]. Circulating log interleukin-6 levels cor-
related positively with IMT and cross-sectional intima-
media area [25]. Reactive aldehydes are involved in the
oxidative modification of low-density lipoprotein (LDL)
cholesterol and foam cell formation. Immunohistochem-
ical analyses of atherosclerotic lesions from human aorta
demonstrated the association of reactive aldehydes with
macrophages and foam cells [26].
Protein damage mediated by ROS results in oxida-
tion of amino residues such as tyrosine. When dityro-
sine is formed, protein aggregation, cross-linking, and
fragmentation occur. These dityrosine-containing cross-
linked protein products were designated AOPPs [17]. Re-
liable markers of the oxidant-mediated protein damage
in ESRD patients, AOPPs behave like mediators of in-
flammation. AOPP levels are increased at an early stage
of chronic renal failure and rise with the progression to
ESRD. AOPPs are found in very high concentrations in
the plasma of dialysis patients and are closely related to
dityrosine. Since patients treated with peritoneal dialy-
sis and patients with preterminal renal failure also have
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significantly higher AOPP levels than do healthy subjects,
Witko-Sarsat et al concluded that uremia per se induces
a significant oxidative stress [17]. A close relationship be-
tween AOPPs and AGE-pentosidine has been observed
both in dialyzed and nondialyzed patients with chronic re-
nal failure (Fig. 1). AOPP levels are also closely related
to plasma levels of monocyte activation markers such as
neopterin, tumor necrosis factor-a, and its soluble recep-
tors [17].
The oxidative stress is attributed to the recurrent ac-
tivation of polymorphonuclear leukocytes (PMNLs) and
monocytes during hemodialysis. PMNL oxidative poten-
tial is involved in plasma AOPP formation. Myeloper-
oxidase, released from phagocytic cells, converts into
hypochlorous acid (HOCl−). Hypochlorite-modified pro-
teins have been detected in human atherosclerotic lesions
[27]. AOPPs represent an exquisite marker of phagocyte-
derived oxidative stress. Myeloperoxidase and the
subsequent generation of chlorinated oxidants are of im-
portance in the formation of AOPPs [28]. Plasma pro-
teins from hemodialysis patients contain elevated levels
of 3-chlorotyrosine [29], a specific product of myeloper-
oxidase catalyzed reaction. The plaques seen after subto-
tal nephrectomy, but also nonatherosclerotic portions of
the intima, stain heavily for nitrotyrosine as a marker of
oxidative stress [6].
In vitro, N-acetylcysteine selectively decreases AOPP-
induced respiratory burst [30]. A significant association of
plasma AOPPs with common carotid artery (CCA)-IMT
and CCA wall-to-lumen ratio has been found in uremic
patients (Fig. 2). AOPP levels correlated with ferritin,
and both parameters were associated with the cumula-
tive intravenous iron dose received during the 12 months
preceding the study. Dru¨eke et al concluded that intra-
venous iron therapy might aggravate oxidative stress and
atherosclerosis of ESRD patients [31].
Recent data from Schwedler et al [32] suggest that
high serum AGE and CML levels in hemodialysis pa-
tients are not linked to increased mortality rates. Since
AGEs are correlated with AOPPs in uremia [17], it is un-
clear whether AOPPs are linked to increased mortality
in these patients. Angiotensin II receptor antagonists and
angiotensin-converting enzyme (ACE) inhibitors lower
in vitro AGE formation [33]. There is lower myeloper-
oxidase release from neutrophils using biocompatible, as
compared to bioincompatible, dialyzers, and also during
anticoagulation with citrate as compared to heparin [34].
An important manifestation of oxidative stress in
uremic patients is an increase in the oxidation of protein-
associated thiol groups and low-molecular-weight
thiol-containing compounds in the plasma. Plasma
aminothiols, such as homocysteine, cysteine, cysteinyl-
glycine, and glutathione are excessively oxidized in
uremia. The ratio of oxidized-to-reduced thiols is consid-
erably increased in hemodialysis patients as compared
to healthy subjects. Oxidized aminothiols thus are can-
didate uremic toxins [35]. Extracellular thiols contribute
an important component in antioxidant defense relevant
to cardiovascular disease by scavenging free radicals and
myeloperoxidase-generated oxidants. Thus, depletion of
reduced thiol groups in the setting of increased reactive
aldehyde production in uremia might favor injury from
oxidant stress [36].
Hyperhomocysteinemia
Hyperhomocysteinemia is highly prevalent in patients
with chronic renal failure and in maintenance dialysis pa-
tients. Circulating homocysteine concentration increases
in a graded manner with decreasing levels of renal func-
tion [4]. Hyperhomocysteinemia in ESRD patients is not
only the result of uremia, folate, or riboflavin deficiency;
relative resistance to the action of folate, vitamin B6, and
vitamin B12; or accumulation of dimethylglycine. It is also
genetically determined [4, 37, 38]. Hyperhomocysteine-
mia has emerged as an independent risk factor for car-
diovascular and cerebrovascular complications such as
ischemic heart disease and stroke in nonuremic patients.
The clinical relevance of elevated total homocysteine lev-
els in the dialysis patient population is uncertain. Clarke,
Lewington, and Landray [39] examined the epidemio-
logic importance of elevated total homocysteine levels
for risk of ischemic heart disease and stroke in apparently
healthy individuals. Among prospective studies, a 25%
lower total homocysteine level was associated with an
11% lower risk of ischemic heart disease and about a 20%
lower risk of stroke. Individuals who had the TT genotype
for methylenetetrahydrofolate reductase (MTHFR), as
compared to those with the CC genotype, had 25% higher
plasma total homocysteine and a 16% higher risk of is-
chemic heart disease [39].
A higher plasma total homocysteine level is associated
with an increased risk of cardiovascular disease in dialysis
patients [40, 41]. The C677T polymorphism for the gene
encoding MTHFR is the most important genetic variant
associated with homocysteine metabolism. Some stud-
ies suggest an association with MTHRF gene mutation,
plasma homocysteine levels, and atherosclerosis; others
did not find such a relationship. Lim, Hung, and Wei [42]
investigated the association between the MTHFR gene
mutation and plasma homocysteine level and carotid
atherosclerosis. They found that patients bearing the TT
genotype had the highest CCA-IMT, whereas the low-
est CCA-IMT values were observed in patients with the
CC genotype. The study failed to demonstrate an associa-
tion between high plasma homocysteine levels and CCA-
IMT values. The investigators concluded that both the TT
genotype and the T allele of the MTHFR gene are asso-
ciated with increased CCA-IMT in hemodialysis patients
[42]. Haviv and coworkers [43] found that hyperhomocys-
teinemia, low serum folate levels, and the MTHFR C667T
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and A1298C mutations were associated with cardiovas-
cular disease in hemodialysis patients. In the general pop-
ulation, moderate elevations of homocysteine might be a
consequence of atherosclerosis or of early renal impair-
ment [44].
In a prospective study, Dudman found that the car-
diovascular risk was 3.6 times higher in hemodialysis
patients with plasma homocysteine >27 lmol/L than
in individuals with levels below that threshold [44]. In
the study by Moustapha et al [40], homocysteine lev-
els were higher in ESRD patients who had fatal and
nonfatal cardiovascular events (43.0 ± 48.6 lmol/L) as
compared with the other patients (26.9 ± 14.9 lmol/L).
The relative risk for cardiovascular events increased
1% per lmol/L increase in total homocysteine concen-
tration [40]. Mallamaci et al [41] tested the prediction
power of total homocysteine in a cohort of 175 hemodial-
ysis patients followed for 29 ± 12 months, taking into
account other risk factors such as C-reactive protein, ane-
mia, and hyperphosphatemia. Combined analysis of fatal
and nonfatal atherothrombotic events showed that ho-
mocysteine was a strong independent predictor of these
outcomes in hemodialysis patients. The hazard ratio for
fatal and nonfatal atherothrombotic events was progres-
sively higher from the first tertile (plasma homocysteine
<22.9 lmol/L) onward, and the hazard ratio of hemodial-
ysis patients with plasma homocysteine in the third tertile
(>37.8 lmol//L) was 8.2 times higher than that for those
in the first tertile (Fig. 3). Dierkes et al [45] found that
homocysteine was associated with all-cause mortality in
hemodialysis patients. In contrast, some studies found no
[46] or even an inverse relationship [47] between the fast-
ing plasma total homocysteine level and the prevalence of
cardiovascular disease in dialysis patients. A positive cor-
relation between predialysis plasma total homocysteine
and albumin concentration might indicate that total ho-
mocysteine is a nutritional and/or inflammatory marker
in dialysis patients. It even has been suggested that within
the dialysis patient population, those with the highest to-
tal homocysteine level have some survival advantages due
to better nutrition [48].
The precise mechanism linking homocysteine with
vascular damage is not fully understood. Plasma ho-
mocysteine is independently related to aortic stiffness
[49] and left-ventricular hypertrophy [50]. Homocys-
teine might cause endothelial injury, endothelial dysfunc-
tion, smooth muscle cell proliferation, and an increase
in vascular monocyte adhesion. Homocysteine-induced
oxidative stress plays a critical role in the process. Ho-
mocysteine at a concentration of 8 lmol/L increases
the binding of lipoprotein(a) to fibrin [51], providing
an important link between homocysteine and clot for-
mation. In the study by Kunz et al [52], a history
of at least one cardiovascular atherothrombotic event
was present in approximately 48% of the maintenance
hemodialysis patients investigated. These events were
independently associated with hyperhomocysteinemia.
The presence of aortic calcifications was independently
and significantly associated with age, hyperhomocys-
teinemia, and fibrinogen concentration. However, none
of the endothelial-hemostatic factors assayed (fibrinogen,
von Willebrand factor, plasminogen activator inhibitor
type 1, and endothelin-1) was related to homocysteine
levels. Folate supplementation decreased plasma homo-
cysteine levels significantly but did not influence the
endothelial-hemostatic markers [52]. Folic acid therapy
improved endothelial function in some studies [53] but
not in another [54]. Ascorbic acid reverses endothe-
lial dysfunction induced by hyperhomocysteinemia [55];
this effect likely is mediated by oxidative stress. Ho-
mocysteine alters the expression of genes known to
modulate cell growth and differentiation and impairs
the cellular antioxidative potential [56]. Hyperhomo-
cysteinemia is associated with asymmetric dimethy-
larginine (ADMA), an endogenous inhibitor of nitric
oxide [57].
Hyperhomocysteinemia raises intracellular S-adenosyl-
homocysteine (AdoHcy) but not AdoMet (methionine)
concentration [58]. Impairment of methylation reactions
increases protein damage. Hypomethylation of DNA can
lead to inappropriate gene expression [59]. Remethyla-
tion and transmethylation rates are significantly lower in
hemodialysis patients as compared to those in healthy
subjects [60].
Relative resistance to potential homocysteine-
lowering therapies, such as treatment with folate, folinic
acid, vitamin B6, or vitamin B12, is present in chronic
renal failure patients. Thus these substances reduce
but do not normalize plasma total homocysteine in this
patient population. Standard hemodialysis with low-flux
dialyzers is unable to remove a sufficient amount of ho-
mocysteine to maintain plasma total homocysteine levels
within the normal range. Intensified dialysis procedures
could potentially normalize plasma total homocysteine
levels in dialysis patients. Daily nocturnal hemodialysis
lowers plasma total homocysteine concentration more
significantly than standard hemodialysis procedures
do [61]. The use of dialyzers with extremely high-flux
and/or absorptive properties also significantly reduces
predialysis plasma total homocysteine levels as com-
pared with traditional high-flux dialyzers [62], probably
because of the removal of albumin by these dialyzers.
At present, not enough data are available to justify
homocysteine-lowering therapies as routine clinical
practice in each patient with chronic renal disease.
Nitric oxide inhibition by ADMA
Impaired endothelium-dependent vasodilation, an
early hallmark of atherosclerosis, has been reported in
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patients with predialysis renal failure and in mainte-
nance hemodialysis patients [63, 64]. Nitric oxide is a
potent anti-atherosclerotic molecule. ADMA accumu-
lates in patients with chronic kidney diseases and in pa-
tients undergoing maintenance dialysis therapy [65–69]
and thus inhibits NOS. Increased plasma ADMA levels
correlate strongly with the severity of the atherosclerotic
disease [66, 70]. In maintenance hemodialysis patients,
plasma ADMA concentrations are not only related to the
severity of atherosclerosis, they are also a predictor of
cardiovascular mortality. Kielstein et al [66] found signifi-
cantly higher ADMA levels in hemodialysis patients with
atherosclerosis as compared to hemodialysis patients
without atherosclerosis (Fig. 4). Patients undergoing dif-
ferent modalities of peritoneal dialysis exhibited lower
plasma ADMA levels than did hemodialysis-treated pa-
tients. The investigators suggested that this difference was
caused by differences in dialytic clearance of ADMA with
the two treatment methods or the metabolism of ADMA.
In contrast, Anderstam, Katzarski, and Bergstro¨m [65]
did not find a difference in plasma ADMA concentra-
tions between peritoneal dialysis and hemodialysis pa-
tients. Zoccali et al [67] investigated the relation between
cardiovascular risk factors and plasma ADMA concen-
tration in 225 hemodialysis patients. They also tested the
predictive power of ADMA for mortality and cardiovas-
cular outcomes. Within 33.4 months, 83 patients had died,
53 (64%) from cardiovascular causes. Plasma ADMA
ranked as the second factor predicting overall mortality
and cardiovascular events [67].
Markedly increased blood concentrations of ADMA
are present even in nonsmoking patients without dia-
betes but with incipient primary renal disease (that is,
patients with normal renal function as documented by
measurement of true glomerular filtration rate using in-
ulin clearance). This increase suggests that the early in-
crease of ADMA levels might be relevant to the excess
cardiovascular morbidity and mortality due to arterio-
and atherosclerotic complications in patients with renal
disease [69]. Plasma ADMA levels also are elevated in
atherosclerotic patients and in hypercholesterolemic sub-
jects with normal renal function [71]. The thickening of
the intima-media complex in middle-aged healthy indi-
viduals with elevated ADMA levels might be caused by
the link between ADMA and endothelial dysfunction
[70]. Zoccali et al [68] investigated the relationship be-
tween plasma ADMA, C-reactive protein, and IMT in
90 maintenance hemodialysis patients. Plasma ADMA
was significantly related to IMT, independently of other
risk factors. In hemodialysis patients with initially normal
IMT, ADMA and C-reactive protein were interacting fac-
tors in the progression of carotid intimal lesions. A signif-
icant relationship between high blood ADMA levels and
reduced renal perfusion in patients with heart failure is
consistent with a causal role of ADMA in the pathophysi-
ology of endothelial dysfunction [72]. Interestingly, ACE
inhibition and angiotensin II AT1-receptor blockade re-
duce ADMA levels in human essential hypertension [73].
Jankowski et al [74] observed inhibition of inducible
NOS (iNOS) expression by plasma obtained from ESRD
patients but not plasma samples from healthy subjects.
The iNOS inhibitor in the plasma of ESRD patients was
identified as phenylacetic acid (PAA). Reduced iNOS
expression might contribute to accelerated atheroscle-
rosis in ESRD patients, since iNOS expression is a
compensatory mechanism when endothelial nitric oxide
production is inadequate. PAA concentration in plasma
of ESRD patients is 3.49 mmol/L, while PAA is not de-
tected in plasma of healthy subjects [74].
Role of phosphate in vascular calcification
Vascular calcification occurs in the development of
atherosclerotic intimal lesions as a consequence of ag-
ing, diabetes, or uremia. Striking differences in plaque
morphology are found between uremic and nonuremic
patients. Heavily calcified plaques were found four times
more frequently in uremic patients than in nonuremic
controls [75]. Vascular calcification is no longer a pas-
sive, degenerative, end-stage process of vascular disease
[76]. Hyperphosphatemia, commonly seen in patients
with chronic renal failure, is highly correlated with the ex-
tent of vascular calcification and vascular disease [77]. A
striking association also exists between serum phospho-
rus levels and mortality rates in maintenance hemodial-
ysis patients [77, 78]. Progressive coronary artery calci-
fication in young hemodialysis patients could be linked
to hyperphosphatemia, to an increased serum calcium ×
phosphate ion product, and to a high daily calcium in-
take, which mostly depends on the intake of calcium-
containing phosphate binders [78]. A recent study by
Jono et al [79] demonstrated that the level of inorganic
phosphate is an important regulator of vascular calcifi-
cation. Human aortic smooth muscle cells (HSMCs) cul-
tured in media containing phosphate levels >1.4 mmol/L
showed dose-dependent increases in mineral deposition
and the expression of the osteoblastic differentiation
markers osteocalcin and Osf2/Cbfa-1, while HSMCs cul-
tured in media containing physiologic levels of inorganic
phosphate did not mineralize (Fig. 5). The authors con-
cluded that elevated phosphate might directly stimulate
HSMCs to undergo phenotypic changes that predispose
to calcification [79]. Transformation of vascular smooth
muscle cells (VSMCs) to calcifying VSMCs (osteoblast-
like cells) occurs not only in the presence of phosphate
but also in response to the action of numerous factors
including AOPPs and AGEs. This process is further in-
creased by infiltrating monocytes/macrophages [80] and
suggests that inflammation and calcification are critically
linked to each other.
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Vascular calcification is prevented by calcification-
inhibiting proteins such as matrix gla protein, osteoprote-
gerin, and fetuin A (a2-Heremans Schmid glycoprotein).
Gla protein has a high affinity for hydroxyapatite [81].
Human fetuin is an important circulating inhibitor of cal-
cification in vivo. Ketteler et al [82] found significantly
decreased fetuin A levels in hemodialysis patients as
compared to healthy controls. The patient group in the
lowest tertile of fetuin A levels had significantly higher
C-reactive protein levels than did patients with normal or
high fetuin A levels, and showed a significantly decreased
cardiovascular and all-cause survival. Low fetuin A lev-
els could be identified as an inflammation-related risk
factor in this cohort of hemodialysis patients. Fetuin defi-
ciency is associated with inflammation in dialysis patients
and might be linked with vascular calcification and mor-
tality in dialysis patients. Fetuin A deficiency also might
explain initiation and development of calciphylaxis [ab-
stract; Westenfeld R, J Am Soc Nephrol 13:219A, 2002].
In the presence of normal or high fetuin A levels, a rel-
ative protection from calcium × phosphate ion product
may prevail.
Recent data from Reslerova and Moe [83] suggest that
vascular calcification in uremic patients is only partially
mediated by hyperphosphatemia. Incubation of vascu-
lar smooth muscle cells with uremic serum augmented
mineralization in vitro as compared to serum obtained
from healthy subjects. Uremic vascular calcification is a
highly regulated process resembling osteogenesis in bone
rather than passive precipitation of mineral excess [84].
The degree of vascular calcification is proportional to
the expression of the bone matrix proteins osteopontin,
bone sialoprotein, alkaline phosphatase, and type I col-
lagen. Uremic serum causes up-regulated expression of
osteopontin, even in the presence of low phosphorus. The
addition of inorganic phosphorus failed to augment the
osteopontin expression induced by uremic serum. In ad-
dition, the effects of uremic serum are only partially in-
hibited by blocking either sodium-phosphate cotransport
or alkaline phosphatase, while the same inhibitors com-
pletely prevented the effect of phosphorus alone [83].
These data suggest a potential role of uremic toxin(s)
in mediating or modulating the development of vascular
calcification in ESRD.
In summary, classic and nonclassic risk factors are in-
volved in arteriosclerosis, atherosclerosis, and vascular
calcification of patients with chronic renal failure [85].
ESRD patients have advanced atherosclerosis and ar-
teriosclerosis as shown by increased arterial wall thick-
ness and increased arterial wall stiffness. Atherosclerosis
refers to the process of intimal plaque formation or
atheroma development, while arteriosclerosis refers to
the hardening or stiffening of arteries. These morphologic
and functional changes are independent predictors of car-
diovascular morbidity and mortality in ESRD patients.
Furthermore, vascular calcification due to the altered
balance of extracellular calcium and phosphorus con-
centrations as well as dysregulation of bone-associated
proteins contribute to the excess mortality in these pa-
tients. Traditional and nontraditional risk factors (AGEs,
ALEs, AOPPs, homocysteine, ADMA, phosphorus) are
involved in arteriosclerosis, atherosclerosis, and vascular
calcification in patients with chronic renal failure. Uremic
toxins contribute to these complications.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Division of Nephrol-
ogy, Tufts-New England Medical Center, Boston,
Massachusetts): Thank you very much for the exhaustive
review of the uremic retention products that might play
a role in atherosclerosis. What should we do to reduce
phosphate levels in uremic patients?
DR. HO¨RL: We have many strategies for lowering
serum phosphorus levels in our patients, but no single
strategy is effective alone. We first recommend to our pa-
tients reduction of phosphate intake, a daily phosphate
intake between 800 mg and 1000 mg. The Austrian popu-
lation particularly has a phosphorus intake between 1200
and 1500 mg per day. Because hyperphosphatemia is a
common complication in our dialysis patient population,
we add phosphate binders. The calcium-containing phos-
phate binders have limitations, however. We cannot of-
fer these drugs to all dialysis patients, particularly not
to ESRD patients with severe hyperphosphatemia, be-
cause a critical increase in the calcium × phosphorus ion
product can induce further complications. Aluminum-
containing phosphate binders also have limitations. Seve-
lamer is a calcium- and aluminum-free phosphate binder
but is not effective enough alone to treat all patients
with hyperphosphatemia. Professor Ritz is working with
an iron-containing phosphate binder. I also know of
some ongoing trials in France with lanthanum-containing
phosphate-lowering substances. Interestingly, long dialy-
sis procedures, particularly daily overnight hemodialysis
as performed by Dr. Pierratos’ group in Canada [86],
normalizes serum phosphate levels, and a majority of
these dialysis patients even need phosphate supplemen-
tation. This is an effective dialysis strategy, but not many
patients are willing to undergo intensive dialysis proce-
dures such as short daily hemodialysis or long nocturnal
hemodialysis.
DR. HARRINGTON: At what level of renal impairment
do you begin to see atherosclerosis? How would early
initiation of dialysis affect the risk for atherosclerosis?
DR. HO¨RL: Atherosclerosis occurs early in patients
with chronic kidney diseases. The group in Hannover
showed a fivefold elevation in the concentration of
plasma ADMA even in patients with incipient renal
disease and normal renal function as a marker of early
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atherosclerosis [69]. I am not familiar with any study
showing that early initiation of dialysis can reduce
atherosclerotic complications. As you know, dialysis can
reduce uremic toxins, but the procedure per se can cause
oxidative stress, which may in fact increase the risk for
atherosclerotic complications. The potential benefits of
earlier dialysis treatment thus might be offset by compli-
cations induced by the dialysis procedure.
DR. J. F. MANN (Department of Nephrology and
Hypertension, Schwabing General Hospital, Mu¨nchen,
Germany): If I understood you correctly, the atheroscle-
rotic plaque in uremic patients contains more calcium
than does the atherosclerotic plaque in nonuremic pa-
tients. My question is related to our use of vitamin D.
On the one hand, vitamin D suppresses hyperparathy-
roidism; on the other hand, it affects calcium metabolism
and also affects major players such as cyclin kinase in-
hibitors, transforming growth factor-b on the atheroscle-
rotic process at the cellular level. How do you envisage
the role of vitamin D in the atherosclerotic process of
uremic patients?
DR. HO¨RL: It is very difficult to separate atheroscle-
rosis, arteriosclerosis, and vascular calcification in ESRD
patients or in patients with chronic renal diseases. You are
right: therapy with vitamin D analogues might raise the
risk for increasing the calcium × phosphorus ion product
by increasing intestinal calcium and phosphate absorp-
tion. To my knowledge, most of the newer vitamin D ana-
logues have a broader window but still we encounter the
problem of an increased calcium × phosphorus ion prod-
uct. Calcimimetics might overcome the problems; several
studies have shown that they reduce serum phosphorus
levels, mildly reduce serum calcium levels, significantly
reduce parathyroid hormone levels, and significantly re-
duce the calcium × phosphorus ion product [87]. In the
long-term, such patients might need to be supplemented
with low-dose vitamin D or vitamin D analogues to avoid
hypocalcemia.
DR. WANNER (Division of Nephrology, Department of
Medicine, University Hospital, Wu¨rzburg, Germany): You
mentioned our data on AGEs [88] and the conflicting
data from Sweden on plasma homocysteine levels [89].
Ed Lowrie demonstrated “reverse epidemiology” when
he linked low cholesterol to high mortality rates [89], and
this is driven mainly by the confounding factor of inflam-
mation. My question is, is C-reactive protein different in
different populations? For example, do Japanese people
have lower C-reactive protein levels? How do C-reactive
protein levels compare in Vienna and southern Italy and
Sweden? Is inflammation the cause of this reverse epi-
demiology?
DR. HO¨RL: C-reactive protein might be one explana-
tion. C-reactive protein levels might not only depend on
the patient population but also on the dialysis procedure.
I recently asked Bengt Lindholm for an explanation for
the discrepant reports on homocysteine and cardiovascu-
lar risk between Swedish dialysis patients and patients in
other countries. Homocysteine levels are not only related
to C-reactive protein but also to different inflammatory
cytokines. The direction is consistent in all of Dr. Lind-
holm’s studies (personal communication): high plasma
homocysteine levels are better than low homocysteine
levels, because high homocysteine levels are associated
with better nutritional status in the Swedish dialysis pa-
tients. I recently asked Peter Stenvinkel to explain the dif-
ferent findings, but he couldn’t. One could speculate that
genetic factors explain the differences between southern
Italy, a population with low atherosclerotic risk factors,
and Sweden.
DR. EBERHARDT RITZ (Klinikum der Universita¨t
Heidelberg, Sektion Nephrologie, Heidelberg, Germany):
Adverse effects of vitamin D go beyond calcification. In
animal models, vitamin D promoted plaque formation
[90] and intimal hyperplasia after injury [91]. Merke et
al and I had demonstrated that endothelial cells express
vitamin D receptors [92], which are paradoxically upreg-
ulated in the vasculature during vitamin D intoxication
[93]. Furthermore, local synthesis of 1,25(OH)2D3 by en-
dothelial cells is activated by inflammatory signals [94]
and possibly creates a self-reinforcing pathogenetic loop.
All this might explain the observation by Milliner et al
that a history of vitamin D treatment was a uniquely ef-
fective predictor of vascular calcification in children [95].
In view of these findings, the administration of highly
supraphysiologic doses of vitamin D is problematic. The
fact that a local 1a-hydroxylase activity is present also
strongly argues against recommendations to correct vita-
min D deficiency by administering high doses of chole-
calciferol.
I have a further comment. You stated that Kielstein
found elevated ADMA concentrations, “. . . even in pa-
tients with normal glomerular filtration rate [69].” The
interpretation that this constitutes a paradox has been
given on many occasions, but I feel there is a very simple
explanation. Because single-nephron hyperfiltration oc-
curs after renal injury, patients can have a normal whole-
kidney glomerular filtration rate despite loss of up to
40% of functional, metabolically active parenchyma. This
just illustrates how poor the instruments are with which
nephrologists assess renal function, that is, by measuring
whole kidney.
DR. HO¨RL: May I briefly respond to your first com-
ment. Clearly I am familiar with some additional effects
of vitamin D compounds. It was the intention of this pre-
sentation to focus exclusively on toxins.
DR. RITZ: With respect to vitamin D data, many
nephrologists have been misled into using megadoses
of active vitamin D without considering its vascular
effects. Now the question, and I return to what Dr.
Wanner asked. Discrepant reports have been published
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concerning serum homocysteine concentrations and car-
diovascular risk in renal patients. I am not very familiar
with the primary literature. One important determinant is
methionine and the methionine load. Has this been care-
fully standardized? I assume that often studies in dialysis
patients have been analyzed post meal in the afternoon
shifts.
DR. HO¨RL: This is a good point. The methionine load
has not been standardized, but many data have been
published before and after a load with this single amino
acid. Endothelial function and endothelial dysfunction
have been studied before and after methionine load,
and also with and without antioxidative vitamin therapy.
Some publications suggest that methionine affects en-
dothelial function in ESRD patients. One 6-hour dwell
with a commercial amino acid dialysis solution contain-
ing methionine impaired forearm reactive hyperemia in
peritoneal dialysis patients as compared to glucose-based
dialysis solutions [96]. Chambers et al demonstrated that
hyperhomocysteine-associated impairment of vascular
endothelial function can be prevented by pretreatment
with vitamin C in healthy subjects [55]. So oxidative stress
might be involved. On the other hand, van Guldener et al
found that folic acid therapy was without any effect in the
peritoneal dialysis [54] and hemodialysis patient popula-
tions [97]. Again, controversy exists not only regarding
plasma homocysteine but also regarding the effects of
methionine, the role of oxidative stress, and the possibil-
ities of antagonizing these effects.
DR. HARRINGTON: Which of the several factors that
you and other people have discussed might be quantita-
tively the most relevant? Has experimental renal disease
been superimposed on experimental cardiovascular dis-
ease?
DR. HO¨RL: The problem is that such a model does not
really reflect the clinical situation, as our dialysis popula-
tion has so many risk factors that work together. I will give
you an example: If you look at the correlation between
mortality rate in ESRD patients and total cholesterol, you
will not find a correlation. If you look at the mortality rate
and LDL cholesterol, you also will not find a correlation.
This does not exclude the fact that lipid abnormalities
have an additive effect on the other risk factors. As we
learned recently from data published by Dr. Nishizawa’s
group [98], the non-HDL-cholesterol fraction might be a
risk factor for these patients despite high apolipoprotein
A IV levels. Thus, such a model also should include lipid
abnormalities and insulin resistance.
DR. F. KELLER (Division of Nephrology, Medical Fac-
ulty, University of Ulm, Ulm, Germany): You mentioned
that the patient was treated by parathyroidectomy. Did
she benefit from this operation? When I started in
nephrology 25 years ago, Shaul Massry always said that
the most important uremic toxin is parathyroid hormone.
Did this patient benefit from that procedure?
DR. HO¨RL: Parathyroid hormone is an important ure-
mic toxin. On the other hand, data indicate that the
parathyroid hormone–related peptide protects against
calcification and might protect against atherosclerosis. I
know that in Ulm you use the opposite strategy than we
do in Vienna. I am familiar with your publication in the
American Journal of Kidney Disease indicating that you
favor total parathyroidectomy without implantation of
one of the removed glands [99]. If you asked our surgeon,
however, Professor B. Niederle, he would tell you that
close to 90% of his patients have been treated success-
fully by parathyroidectomy. Also, the patient presented
here underwent total parathyroidectomy with implanta-
tion of one gland.
DR. KELLER: May I also add a personal observa-
tion. We have observed patients treated by hemodial-
ysis for 20 or 30 years, and all these patients surviv-
ing such a long time on hemodialysis have had total
parathyroidectomy.
DR. HO¨RL: I personally believe that prevention of
an increased calcium × phosphorus ion product and in-
creased intracellular calcium accumulation by parathy-
roidectomy or adequate use of vitamin D or vitamin D
analogues to prevent secondary hyperparathyroidism is
very important for these patients.
DR. J. PLUM (Klinik fu¨r Nephrologie, Klinikum
Kassel, Kassel, Germany): I would like to focus on the
question about sodium and water as direct or indirect tox-
ins in patients with moderate renal insufficiency. We know
that moderate renal insufficiency is accompanied by an
increase of extracellular volume, and these patients de-
velop hypertension, not only volume-dependent hyper-
tension, but also vasoconstriction-induced hypertension,
because of an increase in intracellular calcium. Do you
see a link among water, extracellular volume, and arterial
hypertension that is the major risk factor for atheroscle-
rosis?
DR. HO¨RL: I recently reviewed the process of hyper-
tension in end-stage renal disease patients with one of
my sons [100]. In fact, extensive data from Ozkahya et al
[101], Shaldon [102], Kooman et al [103], and Ozkahya
et al [104] indicate that restricting salt intake and low-
ering sodium concentration in the dialysate can normal-
ize blood pressure in more than 90% of ESRD patients
without the use of antihypertensive medication. Even af-
ter 3 years of sodium restriction in the study by Ozkahya
et al [104], patients were compliant with a low sodium
intake. Again, we in Vienna face the problem that the
Austrian dialysis population eats far too much sodium
chloride, and 80% of our hemodialysis patients are hyper-
tensive despite adequate or excellent hemodialysis ther-
apy. I agree with you that water is also a toxin, and that
this toxin can be markedly reduced by sodium restric-
tion in patients with chronic renal disease and in ESRD
patients.
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DR. B. KRA¨MER (Department of Medicine II, Uni-
versity Hospital, Regensburg, Germany): You elegantly
showed that a wide variety of factors can cause vascular
damage in uremic patients. However, the role of these
factors is unclear. These factors might reflect an early in-
crease in renal damage, or they could be surrogate param-
eters for inflammation. Do clinical trials suggest which of
these factors are involved in vascular damage and what
trials we need to perform in the future?
DR. HO¨RL: In their recent Lancet publication, Zoc-
cali et al demonstrated that ADMA was the second most
important cardiovascular risk factor in a huge hemodial-
ysis patient population [67]. More and more papers have
convincingly shown that ADMA is a major cardiovas-
cular and atherosclerotic risk factor for patients with
chronic renal disease and particularly for ESRD pa-
tients. Before clinical trials demonstrate that reduction in
plasma ADMA concentration really reduces atheroscle-
rotic complications and improves survival in ESRD
patients, I cannot give a general recommendation that
uremic toxins associated with atherosclerosis should be
reduced or normalized.
The next problem is that we do not currently have effec-
tive therapeutic procedures for normalizing these factors.
I mentioned that serum phosphorus can be normalized by
short daily or long nocturnal hemodialysis. Friedman et
al recently showed that plasma total homocysteine lev-
els are normalized by long nocturnal hemodialysis 6 or
7 days a week [61]. Thus, we have strategies for normaliz-
ing some risk factors, but many other atherosclerotic risk
factors such as ADMA can persist in high plasma con-
centrations. Insulin resistance is a further cardiovascular
risk factor for ESRD patients. At present it is unclear
whether uremic toxins are contributing factors to insulin
resistance and whether removal or reduction of such fac-
tors normalizes insulin resistance in these patients.
DR. W. RIEGEL (Med. Klinik III, Klinikum Darmstadt,
Darmstadt, Germany): Acidosis is often present in the
uremic state, and acidosis itself can contribute to uremic
toxicity. Acidosis often is not completely equalized by our
treatment. Can you tell us what acidosis contributes and
which factors are influenced by metabolic acidosis?
DR. HO¨RL: As you know, many patients with chronic
kidney disease, particularly those who arrive at the dialy-
sis unit, have metabolic acidosis. We have several def-
initions of target bicarbonate levels for hemodialysis
patients, such as >20 mmol/L or ≥22 mmol/L. We also
have different target bicarbonate levels at which prob-
lems with metabolic acidosis can occur, for example, <18
mmol/L or ≤15 mmol/L. Several years ago, Dr. Ritz and
I tried to show that metabolic acidosis increases plasma
levels of parathyroid hormone, and that correction of
metabolic acidosis results in a decrease of parathyroid
hormone levels. Our one study, however, showed an ef-
fect of correction of metabolic acidosis on parathyroid
hormone production [105]. This finding does not elim-
inate the possibility that metabolic acidosis contributes
to the increase of some of the uremic toxins, and that
metabolic acidosis is indirectly linked to atherosclerosis
and vascular calcification. I am not familiar with a study
showing that metabolic acidosis is directly connected to
atherosclerosis, however.
DR. G. HELLIGE (Essen): You referred to peripheral
occlusive disease. A couple of years ago I read a study
from Hannover in which the authors treated stage II
peripheral occlusive disease with a supplementation of
16 g/day of L-arginine [106]. One can speculate that
supplementation with L-arginine overcomes the prob-
lem of elevated ADMA levels by increasing nitric oxide
synthesis.
DR. HO¨RL: This is an interesting concept: loading the
patient with the substrate L-arginine to increase nitric
oxide synthesis and overcome the inhibitory effect of
ADMA on nitric oxide synthesis. Such a long-term strat-
egy could be limited by patient compliance and prob-
ably also by adverse events. But it is worth consider-
ing this concept. An alternative strategy could be re-
duction of plasma ADMA levels using angiotensin II
receptor blockers and/or ACE inhibitors in ESRD pa-
tients. What confuses me with the ADMA data is that
peritoneal dialysis patients have the same or a compara-
ble risk for atherosclerosis as do hemodialysis patients,
but the ADMA levels in peritoneal dialysis patients are
markedly lower than in hemodialysis patients [66]. One
can argue that lower ADMA levels in peritoneal dialysis
patients are counterbalanced by higher total cholesterol,
higher LDL cholesterol, and higher triglyceride levels, as
well as by higher blood pressure values, particularly in
patients with reduced residual renal function.
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